Related references
Note: Only part of the references are listed.An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort
Penny Watson et al.
RHEUMATOLOGY (2015)
Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus - the Hopkins Lupus Cohort
Sarah Al Sawah et al.
LUPUS SCIENCE & MEDICINE (2015)
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports
C. Bexelius et al.
LUPUS (2013)
2013 Update: Hopkins Lupus Cohort
Monthida Fangtham et al.
CURRENT RHEUMATOLOGY REPORTS (2013)
Incidence of and Risk Factors for Adverse Cardiovascular Events Among Patients With Systemic Lupus Erythematosus
Laurence S. Magder et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2012)
Predictors of Organ Damage in Systemic Lupus Erythematosus The Hopkins Lupus Cohort
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2012)
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort
M. B. Urowitz et al.
ARTHRITIS CARE & RESEARCH (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus
Robert Biesen et al.
ARTHRITIS RESEARCH & THERAPY (2011)
The Efficacy and Safety of Abatacept in Patients With Non-Life-Threatening Manifestations of Systemic Lupus Erythematosus Results of a Twelve-Month, Multicenter, Exploratory, Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial
J. T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Prednisone, Lupus Activity, and Permanent Organ Damage
Mae Thamer et al.
JOURNAL OF RHEUMATOLOGY (2009)
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study
Johanna Gustafsson et al.
ARTHRITIS RESEARCH & THERAPY (2009)
EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics
G. Bertsias et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
KP Baker et al.
ARTHRITIS AND RHEUMATISM (2003)
Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study
A Ravelli et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2003)
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus - A double-blind, randomized, placebo-controlled trial
MA Petri et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
